JP6010037B2 - 腫瘍浸潤全ｔリンパ球の分析に基づいて、がん患者の生存指標を測定する方法 - Google Patents
腫瘍浸潤全ｔリンパ球の分析に基づいて、がん患者の生存指標を測定する方法 Download PDFInfo
- Publication number
- JP6010037B2 JP6010037B2 JP2013532230A JP2013532230A JP6010037B2 JP 6010037 B2 JP6010037 B2 JP 6010037B2 JP 2013532230 A JP2013532230 A JP 2013532230A JP 2013532230 A JP2013532230 A JP 2013532230A JP 6010037 B2 JP6010037 B2 JP 6010037B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- otl
- tumor
- cells
- analysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 156
- 210000001744 T-lymphocyte Anatomy 0.000 title claims description 82
- 238000000034 method Methods 0.000 title claims description 69
- 201000011510 cancer Diseases 0.000 title claims description 62
- 238000004458 analytical method Methods 0.000 title claims description 48
- 230000004083 survival effect Effects 0.000 title claims description 43
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 86
- 210000004027 cell Anatomy 0.000 claims description 83
- 210000001519 tissue Anatomy 0.000 claims description 81
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 78
- 206010009944 Colon cancer Diseases 0.000 claims description 40
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 33
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims description 30
- 206010033128 Ovarian cancer Diseases 0.000 claims description 30
- 230000011987 methylation Effects 0.000 claims description 30
- 238000007069 methylation reaction Methods 0.000 claims description 30
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims description 27
- 108020004414 DNA Proteins 0.000 claims description 26
- 238000011529 RT qPCR Methods 0.000 claims description 26
- 206010006187 Breast cancer Diseases 0.000 claims description 24
- 208000026310 Breast neoplasm Diseases 0.000 claims description 24
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 22
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 20
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 16
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 16
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 238000005259 measurement Methods 0.000 claims description 12
- 108091029523 CpG island Proteins 0.000 claims description 11
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 10
- 238000001369 bisulfite sequencing Methods 0.000 claims description 8
- 108700039887 Essential Genes Proteins 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 230000017858 demethylation Effects 0.000 claims description 6
- 238000010520 demethylation reaction Methods 0.000 claims description 6
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 5
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 5
- 210000001672 ovary Anatomy 0.000 claims description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 102100038077 CD226 antigen Human genes 0.000 claims description 3
- -1 CD45RA Proteins 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 3
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims description 3
- 102100039844 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-T2 Human genes 0.000 claims description 3
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 3
- 101000887521 Homo sapiens Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-T2 Proteins 0.000 claims description 3
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims description 3
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 claims description 3
- 101000620662 Homo sapiens Serine/threonine-protein phosphatase 6 catalytic subunit Proteins 0.000 claims description 3
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 3
- 101000818605 Homo sapiens Zinc finger and BTB domain-containing protein 32 Proteins 0.000 claims description 3
- 102100022341 Integrin alpha-E Human genes 0.000 claims description 3
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 claims description 3
- 102100022345 Serine/threonine-protein phosphatase 6 catalytic subunit Human genes 0.000 claims description 3
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 3
- 108700009124 Transcription Initiation Site Proteins 0.000 claims description 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 3
- 102100021135 Zinc finger and BTB domain-containing protein 32 Human genes 0.000 claims description 3
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 101150027879 FOXP3 gene Proteins 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 238000001976 enzyme digestion Methods 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 239000000523 sample Substances 0.000 description 25
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 21
- 210000003289 regulatory T cell Anatomy 0.000 description 21
- 230000001973 epigenetic effect Effects 0.000 description 20
- 230000002611 ovarian Effects 0.000 description 20
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 108091093088 Amplicon Proteins 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 238000004393 prognosis Methods 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 10
- 210000003162 effector t lymphocyte Anatomy 0.000 description 10
- 210000002865 immune cell Anatomy 0.000 description 9
- 230000007067 DNA methylation Effects 0.000 description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 201000004101 esophageal cancer Diseases 0.000 description 8
- 230000008595 infiltration Effects 0.000 description 8
- 238000001764 infiltration Methods 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 238000011002 quantification Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 208000029742 colonic neoplasm Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010014733 Endometrial cancer Diseases 0.000 description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 6
- 201000002528 pancreatic cancer Diseases 0.000 description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 description 4
- 101000738413 Homo sapiens T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 description 4
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 description 4
- 102100037911 T-cell surface glycoprotein CD3 gamma chain Human genes 0.000 description 4
- 238000011394 anticancer treatment Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000002601 intratumoral effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 230000035131 DNA demethylation Effects 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 101000800807 Homo sapiens Tumor necrosis factor alpha-induced protein 8 Proteins 0.000 description 2
- 101000759545 Homo sapiens Zinc finger and BTB domain-containing protein 7B Proteins 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100023265 Zinc finger and BTB domain-containing protein 7B Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000007419 epigenetic assay Methods 0.000 description 2
- 230000004049 epigenetic modification Effects 0.000 description 2
- 230000006718 epigenetic regulation Effects 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 102000053917 human FOXP3 Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000013394 immunophenotyping Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000011430 maximum method Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000002501 natural regulatory T cell Anatomy 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 201000003733 ovarian melanoma Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- 101150060950 CD3D gene Proteins 0.000 description 1
- 101150017312 CD3G gene Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000410536 Esme Species 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 238000001337 Mantel test Methods 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 238000003646 Spearman's rank correlation coefficient Methods 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102100033649 Tumor necrosis factor alpha-induced protein 8 Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004034 genetic regulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000005024 intraepithelial lymphocyte Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012420 spiking experiment Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10187046 | 2010-10-08 | ||
| EP10187046.7 | 2010-10-08 | ||
| PCT/EP2011/067660 WO2012045888A1 (en) | 2010-10-08 | 2011-10-10 | Method for determining cancer patient survival based on analyzing tumor-infiltrating overall t-lymphocytes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013544502A JP2013544502A (ja) | 2013-12-19 |
| JP2013544502A5 JP2013544502A5 (enExample) | 2014-11-27 |
| JP6010037B2 true JP6010037B2 (ja) | 2016-10-19 |
Family
ID=44802051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532230A Expired - Fee Related JP6010037B2 (ja) | 2010-10-08 | 2011-10-10 | 腫瘍浸潤全ｔリンパ球の分析に基づいて、がん患者の生存指標を測定する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130260378A1 (enExample) |
| EP (1) | EP2625288B1 (enExample) |
| JP (1) | JP6010037B2 (enExample) |
| CA (1) | CA2814150A1 (enExample) |
| WO (1) | WO2012045888A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201221133D0 (en) | 2012-11-23 | 2013-01-09 | Epiontis Gmbh | Epigenetic method for the identification of subpopulations of CD8 and T lympocytes, in particular CD8 alpha and beta T lymphocytes |
| GB201516971D0 (en) * | 2015-09-25 | 2015-11-11 | Epiontis Gmbh | MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells |
| GB201516972D0 (en) * | 2015-09-25 | 2015-11-11 | Epiontis Gmbh | LRP5 as epigenetic marker for the identification of immune cells, in particular B-cells |
| DE102016005947B3 (de) * | 2016-05-16 | 2017-06-08 | Dimo Dietrich | Verfahren zur Abschätzung der Prognose und zur Prädiktion des Ansprechens auf eine Immuntherapie von Patienten mit malignen Erkrankungen |
| US11685955B2 (en) | 2016-05-16 | 2023-06-27 | Dimo Dietrich | Method for predicting response of patients with malignant diseases to immunotherapy |
| JP7061342B2 (ja) * | 2018-03-14 | 2022-04-28 | 学校法人 愛知医科大学 | エフェクター制御性ｔ細胞の検出及び調製 |
| DE102018116353B4 (de) * | 2018-07-05 | 2020-06-10 | Epiontis Gmbh | Verfahren zum Nachweis und zur Zählung epigenetischer Immunzellen in humanen Blutproben für Immundiagnostik und Neugeborenen-Screening |
| WO2021077063A1 (en) * | 2019-10-18 | 2021-04-22 | Washington University | Methods and systems for measuring cell states |
| WO2024254366A1 (en) | 2023-06-09 | 2024-12-12 | Dow Global Technologies Llc | Method for producing corrugated laminated panels |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002171973A (ja) | 2000-12-07 | 2002-06-18 | Univ Tokyo | Ｄｎａメチル化パターンによる細胞の同定法 |
| AU2003285586A1 (en) | 2002-12-03 | 2004-06-23 | Medical Research Council | Regulatory t-cells |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| DK1826279T3 (da) | 2006-02-28 | 2011-09-05 | Charite Universitaetsmedizin | Detektering og kvalitetskontrol af regulatoriske t-celler vha. DNA-metyleringsanalyse af FoxP3--genet |
| EP2141245A1 (en) * | 2008-07-03 | 2010-01-06 | Ivana Türbachova | DNA methylation analysis of regulatory T cells through DNA-methylation analysis of the TSDR region of the gene foxP3 |
| DK2199411T3 (en) * | 2008-12-16 | 2015-08-03 | Epiontis Gmbh | Epigenetic markers for the identification of CD3-positive T lymphocytes |
-
2011
- 2011-10-10 CA CA2814150A patent/CA2814150A1/en not_active Abandoned
- 2011-10-10 WO PCT/EP2011/067660 patent/WO2012045888A1/en not_active Ceased
- 2011-10-10 EP EP11770415.5A patent/EP2625288B1/en active Active
- 2011-10-10 JP JP2013532230A patent/JP6010037B2/ja not_active Expired - Fee Related
- 2011-10-10 US US13/825,691 patent/US20130260378A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2814150A1 (en) | 2012-04-12 |
| EP2625288B1 (en) | 2016-05-25 |
| JP2013544502A (ja) | 2013-12-19 |
| WO2012045888A1 (en) | 2012-04-12 |
| US20130260378A1 (en) | 2013-10-03 |
| EP2625288A1 (en) | 2013-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6010037B2 (ja) | 腫瘍浸潤全ｔリンパ球の分析に基づいて、がん患者の生存指標を測定する方法 | |
| Clarke et al. | Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss | |
| US20190376148A1 (en) | Diagnostic for lung disorders using class prediction | |
| JP7228896B2 (ja) | 乳がん患者の予後の予測方法 | |
| Hrašovec et al. | TMEM25 is a candidate biomarker methylated and down‐regulated in colorectal cancer | |
| US20090047656A1 (en) | Molecular analysis of primary cells | |
| Roa et al. | Identification of a new microRNA expression profile as a potential cancer screening tool | |
| CA2836844A1 (en) | Biomarkers for lung cancer | |
| Eggers et al. | Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma | |
| JP2024020392A (ja) | 特定の遺伝子のｃｐｇメチル化変化を利用した肝癌診断用組成物およびその使用 | |
| JP6543573B2 (ja) | ＣＤ８＋Ｔリンパ球、特にＣＤ８α及びβＴリンパ球の亜集団の同定用のエピジェネティック法 | |
| TW201827603A (zh) | 用於膀胱癌預後的生物標記物組合 | |
| CN110023510A (zh) | 作为卵巢癌预后诊断标志物的mmp1基因转录产物和检测方法 | |
| WO2017119510A1 (ja) | 乳がんの診断のための検査方法、遺伝子マーカー、および検査薬 | |
| Ma et al. | Methylation-independent CRIP1 expression is a potential biomarker affecting prognosis in cytogenetically normal acute myeloid leukemia | |
| Smit et al. | High‐resolution ERG‐expression profiling on G eneChip exon 1.0 ST arrays in primary and castration‐resistant prostate cancer | |
| JP2022548993A (ja) | Ｄｎａメチル化異常を用いた免疫抗癌治療反応性予測方法 | |
| Cheng et al. | Expression of survivin and its splice variants in gastric cancer | |
| CA2599055C (en) | Neoplasia screening compositions and methods of use | |
| JP2014501496A (ja) | 消化管間質腫瘍における臨床転帰のシグネチャーおよび消化管間質腫瘍の治療の方法 | |
| Ploussard et al. | The prognostic value of FGFR3 mutational status for disease recurrence and progression depends on allelic losses at 9p22 | |
| US20220136069A1 (en) | Macrophage expression in breast cancer | |
| JP2015177745A (ja) | 肺癌の検査方法 | |
| Wang et al. | Molecular detection of B-cell neoplasms by specific DNA methylation biomarkers | |
| Brajušković et al. | Assessment of possible association between RS378854 and prostate cancer risk in the Serbian population |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141006 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141006 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151028 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160125 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160229 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160324 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160428 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160704 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160802 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160825 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160915 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6010037 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |